PharmaTher Holdings Ltd. (PHRRF)
USD 0.16
(12.59%)
USD 0.16
(12.59%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 3.04 Million CAD | -24.18% |
| 2023 | 4.01 Million CAD | -2.13% |
| 2022 | 4.1 Million CAD | 45.64% |
| 2021 | 2.81 Million CAD | 11727.48% |
| 2020 | 23.81 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.35 Million CAD | 19.42% |
| 2024 Q4 | 386.27 Thousand CAD | -8.39% |
| 2024 Q3 | 421.65 Thousand CAD | -53.94% |
| 2024 Q2 | 915.43 Thousand CAD | -32.38% |
| 2023 Q1 | 1.22 Million CAD | -16.54% |
| 2023 FY | 4.01 Million CAD | -2.13% |
| 2023 Q4 | 1.13 Million CAD | 36.75% |
| 2023 Q3 | 828.9 Thousand CAD | -0.22% |
| 2023 Q2 | 830.69 Thousand CAD | -32.0% |
| 2022 Q4 | 1.46 Million CAD | 34.67% |
| 2022 Q3 | 1.08 Million CAD | 4.81% |
| 2022 Q2 | 1.03 Million CAD | 101.58% |
| 2022 Q1 | 514.47 Thousand CAD | -30.79% |
| 2022 FY | 4.1 Million CAD | 45.64% |
| 2021 Q4 | 743.32 Thousand CAD | 72.76% |
| 2021 FY | 2.81 Million CAD | 11727.48% |
| 2021 Q3 | 430.26 Thousand CAD | -63.11% |
| 2021 Q2 | 1.16 Million CAD | 73.37% |
| 2021 Q1 | 672.78 Thousand CAD | 0.0% |
| 2020 FY | 23.81 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | 16.617% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -126.909% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -15.854% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 89.7% |
| GB Sciences, Inc. | 1.42 Million USD | -114.295% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 10.599% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1283.182% |
| Skye Bioscience, Inc. | 13.54 Million USD | 77.53% |
| Zenith Capital Corp. | 8.94 Million USD | 65.961% |
| Agentix Corp. | 1.37 Million USD | -121.911% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 39.626% |
| Biomind Labs Inc. | 994.18 Thousand USD | -206.189% |
| ContraFect Corporation | 56.88 Million USD | 94.649% |
| CSL Limited | 3.44 Billion USD | 99.912% |
| CytoDyn Inc. | 18.05 Million USD | 83.143% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -63.277% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -681.403% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 94.7% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -632.668% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -102.682% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -229.621% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 91.829% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.445% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -48.586% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.492% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -4.384% |
| Mesoblast Limited | 5.9 Million USD | 48.423% |
| Marizyme, Inc. | 19.23 Million USD | 84.178% |
| Genus plc | 147.7 Million USD | 97.939% |
| Pharming Group N.V. | 225.49 Million USD | 98.65% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 63.496% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -105.855% |
| IMV Inc. | 37.7 Million USD | 91.927% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -9.093% |
| MultiCell Technologies, Inc. | 567.42 USD | -536377.389% |
| ONE Bio Corp. | 6.44 Million USD | 52.76% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.458% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 87.683% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -72.991% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 54.688% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 12276.32% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 80.987% |
| Alpha Cognition Inc. | 9.7 Million USD | 68.636% |
| Enzolytics Inc. | 2.17 Million USD | -39.668% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.801% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -191.579% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -26.576% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.631% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 38.102% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1063.079% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -23.979% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1674.881% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -58.471% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 65.326% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 30.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | 18.747% |
| Helix BioMedix, Inc. | 1.97 Million USD | -54.362% |
| EV Biologics, Inc. | 531.96 Thousand USD | -472.236% |
| Q BioMed Inc. | 3.43 Million USD | 11.422% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 71.988% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.935% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 86.75% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -65.881% |
| HST Global, Inc. | 140.9 Thousand USD | -2060.347% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -127.947% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -170.607% |
| Halberd Corporation | 74.84 Thousand USD | -3967.342% |
| Resverlogix Corp. | 12.71 Million USD | 76.053% |
| Cell Source, Inc. | 4.32 Million USD | 29.622% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -92.742% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | 58.359% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -17373.624% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -23.404% |
| Kadimastem Ltd | 2.41 Million USD | -26.305% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 28.179% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1577.318% |
| LadRx Corporation | 3.81 Million USD | 20.14% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -229.621% |
| Affymax, Inc. | 39.38 Million USD | 92.271% |
| Itoco Inc. | 919.14 Thousand USD | -231.187% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -172.036% |
| Mobile Lads Corp. | 554.54 Thousand USD | -448.932% |
| International Stem Cell Corporation | 5.27 Million USD | 42.249% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | 20.315% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -11994.561% |
| Qrons Inc. | 643.67 Thousand USD | -372.92% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -114.403% |
| SYBLEU INC | 160.87 Thousand USD | -1792.19% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -36.513% |
| Rebus Holdings, Inc. | 664 Thousand USD | -358.446% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -67.596% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -5682.607% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -14863.771% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 91.606% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -88.138% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -313.691% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 2.151% |
| Neutra Corp. | 243.82 Thousand USD | -1148.49% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 82.562% |
| PureTech Health plc | 144.59 Million USD | 97.895% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 85.144% |
| IXICO plc | 4.7 Million USD | 35.329% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 65.396% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.415% |
| CSL Limited | 3.89 Billion USD | 99.922% |
| Cellectis S.A. | 97.32 Million USD | 96.872% |